EXOZYMES INC. Operating Lease Cost
EXOZYMES INC. (EXOZ) reported Operating Lease Cost of $179.46 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-13
- EXOZYMES INC. operating lease, cost for the quarter ending 2026-06-30 was $85.83K, a 8.34% decline year-over-year.
- EXOZYMES INC. operating lease, cost for the quarter ending 2026-03-31 was $93.63K, a 0.00% change year-over-year.
- EXOZYMES INC. operating lease, cost for the quarter ending 2025-12-31 was $93.63K, a 0.00% change year-over-year.
- EXOZYMES INC. operating lease, cost for the quarter ending 2025-09-30 was $93.63K, a 0.00% change year-over-year.
- EXOZYMES INC. operating lease, cost for fiscal 2025 was $374.53K, a 0.00% change from fiscal 2024.
- EXOZYMES INC. operating lease, cost for fiscal 2024 was $374.53K, a 42.00% increase from fiscal 2023.
- EXOZYMES INC. operating lease, cost for fiscal 2023 was $263.76K.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $85.83K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $179.46K 10-Q · filed 2026-08-13 | $273.09K derived: sum of 3 quarters · filed 2026-08-13 | $366.72K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $93.63K 10-Q · filed 2026-05-14 | $187.27K derived: sum of 2 quarters · filed 2026-05-14 | $280.90K derived: sum of 3 quarters · filed 2026-05-14 | $374.53K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $93.63K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $187.27K derived: sum of 2 quarters · filed 2026-03-30 | $280.90K derived: sum of 3 quarters · filed 2026-08-13 | $374.53K 10-K · filed 2026-03-30 |
| 2025-09-30 | $93.63K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $187.26K derived: sum of 2 quarters · filed 2026-08-13 | $280.90K 10-Q · filed 2025-11-13 | $374.53K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $93.63K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $187.26K 10-Q · filed 2026-08-13 | $280.90K derived: sum of 3 quarters · filed 2026-08-13 | $374.53K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $93.63K 10-Q · filed 2026-05-14 | $187.27K derived: sum of 2 quarters · filed 2026-05-14 | $280.90K derived: sum of 3 quarters · filed 2026-05-14 | $374.53K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $93.63K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $187.27K derived: sum of 2 quarters · filed 2026-03-30 | $280.90K derived: sum of 3 quarters · filed 2026-03-30 | $374.53K 10-K · filed 2026-03-30 |
| 2024-09-30 | $93.63K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $187.26K derived: sum of 2 quarters · filed 2025-11-13 | $280.90K 10-Q · filed 2025-11-13 | $362.59K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $93.63K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $187.26K 10-Q · filed 2025-08-12 | $268.96K derived: sum of 3 quarters · filed 2025-08-12 | |
| 2024-03-31 | $93.63K 10-Q · filed 2025-05-12 | $175.33K derived: sum of 2 quarters · filed 2025-05-12 | ||
| 2023-12-31 | $81.70K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $263.76K 10-K · filed 2025-03-31 | ||
| 2023-09-30 | $182.06K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |